Abstract
Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF.
The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy).
Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agents ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits.
Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal.
Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.
Keywords: Postoperative atrial fibrillation, predictors, pathogenesis, pharmacotherapy, ablation
Current Vascular Pharmacology
Title: Postoperative Atrial Fibrillation - What Do We Really Know?
Volume: 8 Issue: 4
Author(s): Maciej Banach, Antonios Kourliouros, Kurt M. Reinhart, Stefano Benussi, Dimitri P. Mikhailidis, Marjan Jahangiri, William L. Baker, Andrea Galanti, Jacek Rysz, John A. Camm, C. Michael White and Ottavio Alfieri
Affiliation:
Keywords: Postoperative atrial fibrillation, predictors, pathogenesis, pharmacotherapy, ablation
Abstract: Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF.
The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy).
Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agents ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits.
Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal.
Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.
Export Options
About this article
Cite this article as:
Banach Maciej, Kourliouros Antonios, M. Reinhart Kurt, Benussi Stefano, P. Mikhailidis Dimitri, Jahangiri Marjan, L. Baker William, Galanti Andrea, Rysz Jacek, A. Camm John, Michael White C. and Alfieri Ottavio, Postoperative Atrial Fibrillation - What Do We Really Know?, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330807
DOI https://dx.doi.org/10.2174/157016110791330807 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Therapy for Myocardial Regeneration
Current Molecular Medicine Ca2+-Handling Proteins and Heart Failure: Novel Molecular Targets?
Current Medicinal Chemistry miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets A Review of the Role of Statins in Heart Failure Treatment
Current Clinical Pharmacology Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design Editorial [Hot Topic: Natural Products for the Healthy Heart (Guest Editor : Dipak K. Das)]
Current Pharmaceutical Biotechnology Iontophoresis: Drug Delivery System by Applying an Electrical Potential Across the Skin
Drug Delivery Letters Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Insulin Resistance and the Renin-Angiotensin-Aldosterone System in Metabolic Syndrome and Obesity-Related Hypertension
Current Hypertension Reviews Strategies to Avoid TAVI-related Acute Kidney Injury
Current Pharmaceutical Design Inhibition of Zinc Metallopeptidases in Cardiovascular Disease - From Unity to Trinity, or Duality?
Current Pharmaceutical Design Clinical Application of Ghrelin
Current Pharmaceutical Design New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
Current Cancer Drug Targets Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design